KIT and thymic carcinoma: KIT mutations are uncommon in thymic carcinoma; however, retrospective studies have shown that KIT-mutated thymic carcinoma has a meaningful clinical response to imatinib, although the association between KIT expression and response to Sunitinib and Sorafenib is uncertain [83,90].